TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE

膀胱癌是泌尿生殖道的第二大常见癌症，也是导致患者死亡的主要原因。预防BC是非常可取的，以减少复发、死亡率和提高生活质量。临床前和临床资料表明AR信号在BC不同阶段的潜在作用。鉴于AR信号与膀胱癌进展之间的密切联系，FDA批准的下一代AR拮抗剂阿帕鲁胺可以在NMIBC中提供预防策略，以减缓MIBC的进展。这项任务的总体目标是确定阿帕鲁胺对N-丁基-N(4-羟基丁基)亚硝胺(BBN)诱导的大鼠膀胱癌的疗效。任务顺序将评估定义明确的预测生物标记物，以预测阿帕鲁胺对膀胱癌的抑制作用。

Bladder cancer (BC) is the second-most common cancer of the genitourinary tract and also the major cause of death in patients. Preventing BC is highly desirable to reduce recurrence, mortality and improve quality of life. Preclinical and clinical data indicate the potential role of AR signaling in different stages of BC. In view of the strong link between AR signals and bladder cancer progression, apalutamide, a FDA approved next-generation AR antagonist, could provide a preventive strategy in NMIBC to mitigate progression to MIBC. The overall objective of this task order is to determine the efficacy of Apalutamide against N-butyl-N(4-hydroxybutyl) nitrosamine (BBN) induced rat urinary bladder cancers. The task order will assess welldefined predictive biomarkers of bladder cancer inhibition by apalutamide.